G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells  by Fukuchi, Kunihiko et al.
 .Biochimica et Biophysica Acta 1357 1997 297–305
G1 accumulation caused by iron deprivation with deferoxamine does not
accompany change of pRB status in ML-1 cells
Kunihiko Fukuchi a,), Shigeru Tomoyasu b, Hiroyuki Watanabe a, Nobuyoshi Tsuruoka b,
Kunihide Gomi a
a Department of Clinical Pathology, School of Medicine, Showa Uni˝ersity, 1-5-8 Hatanodai, Shinagawaku, Tokyo Japan
b Department of Hematology, School of Medicine, Showa Uni˝ersity, 1-5-8 Hatanodai, Shinagawaku, Tokyo Japan
Received 18 July 1996; revised 23 December 1996; accepted 26 February 1997
Abstract
 .We analyzed G1 accumulation induced by the iron chelator deferoxamine B mesylate DFO compared it with that
 .caused by etoposide and cytosine arabinoside AraC . The results showed that p53 protein increased with all three
treatments without an increase in p53 mRNA. After treatment for 3 or 6 h, p21 mRNA increased with 10y4 DFO to 159%
or 556% of pretreatment levels, to 509% or 391% with 10y5 etoposide, and to 263% or 304% with 10y5 AraC. Induction of
p21 protein was not observed with fluorescence activated cell sorting and Western blot analysis after treatment with DFO or
AraC. Treatment with DFO did not cause any change in levels of CDK4 mRNA or protein, whereas etoposide or AraC
treatment did diminish CDK4 protein. Enzyme linked immunosorbent assay for pRB and its phosphorylation, which reflects
CDK4 activity, revealed that treatment with DFO did not change the amount of pRB or the phosphorylation status. Results
of this investigation show that the mechanism of G1 accumulation induced by DFO involves a p53-independent pathway
and that expression of p21 protein may be regulated posttranscriptionally. q 1997 Elsevier Science B.V.
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1. Introduction
 .The iron chelator deferoxamine B mesylate DFO
is known to inhibit DNA synthesis and cell prolifera-
w xtion both in vitro and in vivo 1–3 . DFO is generally
thought to inhibit the iron-requiring enzyme ribonu-
cleotide reductase, thereby altering the supply of
deoxyribonucleotides and decreasing DNA synthesis
w x1 . Growth inhibition by DFO has been reported at
different points of the cell cycle, as shown by accu-
w x w xmulation at the G1-S 4–6 and the G2M phases 7,8 .
)  .Corresponding author. Fax: 81-3 3788-4927; E-mail:
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Cellular responses differ with cell type and DFO
concentration. These observations suggest that more
than one point of the cell cycle is sensitive to DFO.
We have reported that treatment with DFO causes
growth inhibition, as reflected by G1 accumulation
and apoptosis, in the human myelocytic leukemia cell
w xlines HL-60 and ML-1 9,10 . In ML-1 cells, G1
accumulation and accumulation of the tumor suppres-
sor gene product p53, are observed 6 h after DFO
w xtreatment 10 . The increased levels of p53 protein
enhances expression of p21 mRNA, a target for p53
w x10 . Growth is inhibited by DFO immediately after
treatment, as with such DNA-damaging agents as
w xgamma irradiation and antitumor agents 10–15 . Ac-
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cordingly, the growth inhibition by DFO may involve
regulation of cell-cycle checkpoints, as with DNA-
damaging agents, but is unlikely to be due to a
w xdecrease in DNA synthesis 12–15 .
Progression through the G1-S checkpoints requires
 .phosphorylation of Rb protein pRB by D-type cy-
 .clin-cyclin-dependent kinase 4 CDK4 and cyclin
w xE-CDK2 complexes 16–18 . Several CDK inhibitors
 . INK4a INK4bCDKIs , such as p21, p16 , and p15 , have
been shown to bind to this complex and inhibit its
w xkinase activity 19 . p53 protein accumulates in re-
sponse to DNA damage and plays an important role
in cell growth inhibition by inducing p21 transcrip-
tion, inhibiting activity of proliferating-cell nuclear
w xantigen, and blocking translation of CDK4 19,20 .
Analysis of the mechanism by which DFO inhibits
growth is important for the further use of DFO as an
antiproliferative agent. In this investigation, we ana-
lyzed the p53 sequential cascade by examining ex-
pression of p21 and CDK4 mRNA and protein and
the phosphorylation status of pRB after DFO treat-
ment in ML-1 cells. We then compared these results
with those after treatment with a typical DNA-
damaging agent etoposide, and with those of the
 .antimetabolite cytosine arabinoside AraC .
2. Materials and methods
2.1. Cell culture
ML-1 cells, supplied by the Health Science Re-
 .search Resource Bank HSRRB , were cultured in
RPMI 1640 containing 10% fetal calf serum. Defer-
 .oxamine B mesylate M 656.8 was obtained fromr
Ciba-Geigy, Basel, Switzerland. Etoposide and AraC
 .were purchased from Sigma St. Louis, MO, USA .
2.2. Flow cytometric assay
Cells were fixed with 4% paraformaldehyde for 20
min, washed, then incubated with 1 mgrml of anti-
p53 monoclonal antibody DO-7, DAKO, Glostrup,
. Denmark , anti-p21 monoclonal antibody 2G12,
.PharMingen, San Diego, CA, USA or anti-CDK4
 .polyclonal antibody 4802, PharMingen for 1 h on
ice. After washing, cells were incubated with fluores-
cein isothiocyanate-conjugated goat anti-mouse Ig for
. monoclonal antibodies or anti-rabbit Ig for poly-
.clonal antibody for 30 min on ice, washed, stained
with 50 mgrml propidium iodide, then analyzed with
a FACScan flow cytometer Becton Dickinson, Sun-
.nyvale, CA, USA .
2.3. RNA extraction and Northern blot analysis
RNA extraction and Northern blot hybridization
w xwere performed as described previously 10 . p53
 . cDNA supplied by HSRRB , p21 cDNA provided
.by Dr. Noda, Meiji Cell Technology Center, Japan ,
CDK4 cDNA, and b-actin DNA were labeled with
w xdigoxigenin by the random primer method 21 . CDK4
cDNA was generated by a reverse transcription poly-
merase chain reaction using total RNA from the
normal human fibroblast cell line WI38 supplied by
.HSRRB as a template and the following primers:
forward primer, 5XTCTGAGAATGGCTACCTCTC-
G3X; reverse primer, 5XAGCCAACACTCCACATGT-
CC3X. A PCR product of 611 bp was cloned into
 .pT7Blue Novagen, Madison, WI, USA . The cloned
DNA was then confirmed as representing a partial
CDK4 cDNA for comparison with its expected size
of 611 bp and its sequencing analysis. The level of
expression was normalized by comparison with b-
actin mRNA levels. Experiments were repeated three
times independently, and similar results were ob-
tained.
2.4. Western blot and ELISA
 7.Cells 1=10 were lysed in 1 ml of lyse buffer
0.05 M Tris-HCl, pH 8.0, 0.15 M NaCl, 0.1%
Nonidet P-40, 0.01 M EDTA, 0.05 M NaF, 0.01 M
sodium orthovanadate, 2 mgrml aprotinin, 2 mgrml
.leupeptin, and 5 mgrml PMSF . After incubation on
ice for 30 min, the lysate was clarified by ultracen-
trifugation at 30 000 rpm for 30 min at 48C. The cell
lysate was immunoprecipitated with a specific anti-
body, after which the precipitate was separated by
SDS polyacrylamide gel electrophoresis and blotted
to an Hybond Nq membrane Amersham, Amer-
.sham, UK , and then subjected to Western blot analy-
sis using anti-p53 monoclonal antibody DO-7,
. DAKO , anti-p21 monoclonal antibody 2G12,
. PharMingen , anti-CDK4 polyclonal antibody 4802,
. PharMingen , anti-pRB monoclonal antibody G99-
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.73, PharMingen , or anti-phosphorylated serine and
anti-phosphorylated threonine polyclonal antibodies
 .Zymed Laboratories, San Francisco, CA, USA . En-
 .zyme-linked immunosorbent assay ELISA to quan-
tify pRB and the phosphorylation status of pRB was
performed as follows. Polystyrene beads were coated
with an anti-pRB monoclonal antibody that recog-
nizes an epitope between amino acids 240–384 of
 .human pRB G99-73, PharMingen in 0.1 M phos-
 .phate pH 7.0 . Antibody-coated beads were incu-
bated with 50 mg of cell lysate in 0.1 M phosphate
 .pH 7.0 , 0.1 M NaCl, and 1% BSA at 48C for 8 h.
After washing with wash buffer 0.1 M phosphate
 . .pH 7.0 and 0.1 M NaCl , the beads were incubated
with a rabbit anti-pRB polyclonal antibody that rec-
ognizes an epitope between amino acids 914-928 of
human pRB Ab-2, Oncogene Science, Uniondale,
.NY, USA or rabbit anti-phosphorylated serine and
anti-phosphorylated threonine polyclonal antibodies
 .  .Zymed Laboratories in 0.1 M phosphate pH 7.0 ,
0.5 M NaCl and 1% BSA for 1 h on ice. After
washing with wash buffer, the beads were incubated
with horseradish peroxidase-conjugated anti-rabbit
 .IgG in 0.1 M phosphate pH 7.0 , 0.1 M NaCl and
1% BSA for 1 h on ice. For chemiluminescent detec-
 .tion, 200 ml of substrate, ECL solution Amersham
was added to each bead, after which chemilumines-
cence was measured with Luminescence Reader
 .Aloka, Japan . To quantify the amount of pRB,
recombinant pRB QED Bioscience, San Diego, CA,
.USA was used for the standard assay.
3. Results
3.1. G1 accumulation with DFO treatment
To determine the optimal concentrations of DFO,
etoposide, and AraC for growth inhibition, we added
10y6 to 10y3 M of DFO, etoposide, or AraC to
ML-1 cells in the exponential growth phase, then
monitored their growth with a flow cytometer after 1
to 9 h of incubation. With 10y4 M DFO, 10y5 M
etoposide and 10y5 M AraC, cell growth was inhib-
ited 3 h after the start of treatment and G1 accumula-
tion became apparent 6 h treatment.
Analysis of DNA histograms after 6 h of treatment
showed that 54% of cells treated with 10y4 M DFO
accumulated in the G1 phase, while in untreated cells
the proportion of G1 phase cells was 30%. Treatment
with 10y5 M etoposide caused an increase in the
 .number of cells in the S phase 66% , and treatment
with AraC caused an increase in the number of cells
 .  .in the G1 phase 47% Fig. 1A . G1 accumulation
became apparent on the DNA histogram after 48 h of
y4  .treatment with 10 M DFO Fig. 1B . To analyze
the early cellular response, we used the above-stated
concentrations and the incubation periods of 3 and 6
h for the following experiments.
3.2. P53 expression
Flow cytometric analysis revealed that p53 protein
expression increased after 6 h of treatment with DFO,
 .etoposide, or AraC Fig. 1A . To confirm that the
data from FACS, we examined p53 protein expres-
sion with Western blot analysis. Enhanced p53 pro-
tein bands were detected in lysates of cells treated
 .with DFO, etoposide, or AraC Fig. 2A . The data
from FACS and Western blot analysis were well
correlated. The levels of p53 mRNA as determined
by Northern blot analysis demonstrated that the
mRNA level remained almost unchanged after 3 to 6
h of treatment with DFO, etoposide, or AraC Fig.
.3A .
3.3. P21 expression
To determine whether the p53 growth inhibition
cascade p53 induction of p21 expression, with p21
inhibiting cyclin-CDK kinase activity, which reduces
.Rb phosphorylation is involved in DFO-induced G1
accumulation, we examined the expression of p21
mRNA and protein. As shown in Fig. 3B, after
incubation for 3 h, the level of p21 mRNA increased
y5 significantly with 10 M etoposide 509% of levels
.in untreated cells and increased to some extent with
y4  . y5  .10 M DFO 159% and 10 M AraC 263% .
After incubation for 6 h, p21 mRNA levels increased
markedly with all three treatments: 556% with 10y4
M DFO, 391% with 10y5 M etoposide, and 304%
with 10y5 M AraC. The expression of p21 protein
showed a marked increase after etoposide treatment
 .for 6 h Fig. 1A . Although mRNA expression was
enhanced after treatment with DFO or AraC for 3 and
6 h, p21 protein expression remained at the level of
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Fig. 2. Western blot analysis of p53 and CDK4. Cells were
harvested 6 h after the addition of 10y4 M DFO, 10y5 M
etoposide, or 10y5 M AraC and lysed with 1% NP40. Cell
lysates were immunoprecipitated with anti-p53 monoclonal anti-
body or anti-CDK4 polyclonal antibody. The precipitates were
electrophoresed in 10% to 20% SDS-PAGE, transferred to Hy-
bond Nq membrane, then probed with anti-p53 monoclonal
 .  .antibody A or anti-CDK4 polyclonal antibody B . UT: un-
treated, DFO: deferoxamine, Etop: etoposide.
 .untreated cells Fig. 1A . To determine whether p21
protein increased transiently with DFO or AraC, we
also examined other time points. No increase in p21
protein was detected after incubation for 1 to 12 h
 .data not shown .
It is possible that FACS failed to detect the p21
protein in the form of cyclin-CDK complex after
paraformaldehyde fixation. To confirm that p21 pro-
tein synthesis is enhanced only after treatment with
etoposide, we conducted Western blot analysis of cell
lysates. First, to detect the p21 protein in a cyclin-
CDK4 complex, the cell lysate was immunoprecipi-
tated with anti-CDK4 polyclonal antibody, after which
the precipitate was probed with anti-p21 monoclonal
antibody. Second, to detect p21 protein in any com-
plexed form, the cell lysate was treated with 0.01%
SDS and 0.1% sodium deoxycolate to dissociate the
complex, immunoprecipitated with anti-p21 mono-
clonal antibody, then probed with anti-p21 mono-
clonal antibody. The protein product of p21 was
observed in the lysate of only etoposide-treated cells
 .Fig. 4 .
3.4. CDK4 expression
CDK4 is one of the most important factors control-
ling progression through the G1 checkpoint. Since
DFO treatment causes G1 accumulation, we have
examined the involvement of CDK4 in this process.
To identify the level of regulation of CDK4 by DFO,
we analyzed CDK4 mRNA and protein expression.
CDK4 mRNA levels were not affected by treatment
 .with DFO, etoposide, or AraC for 3 or 6 h Fig. 3C ,
indicating that transcriptional regulation was not oc-
curring. The CDK4 staining pattern showed that
CDK4 protein expression after treatment with DFO
 .was similar to that in untreated cells Fig. 1A . After
treatment with etoposide or AraC, CDK4 expression
of G1-phase cells was similar to that of untreated
cells and decreased in phases S through G2M Fig.
.1A . We further examined the CDK4 protein expres-
sion with Western blot analysis. The intensity of the
CDK4 protein band correspond to the FACS data
 .Fig. 2B .
3.5. pRB phosphorylation status
To investigate CDK4 function, we examined the
phosphorylation status of pRB. On Western blot anal-
ysis, phosphorylated pRB appeared as a more slower
migrating band, and unphosphorylated pRB appeared
as a more quickly migrating band, similar to that
 .obtained from a confluent WI38 cell lysate Fig. 5A
w x22 . After 6 h of treatment, phosphorylated and
unphosphorylated pRB bands were observed in lysates
from both untreated and DFO-treated cells. With
etoposide treatment, the band appeared between the
phosphorylated and unphosphorylated pRB bands
 .Fig. 5A . To confirm that more slowly migrating
band represented phosphorylated pRB, anti-pRB im-
munoprecipitates were subjected to Western blot
analysis with anti-phosphorylated serine and threo-
nine antibodies. Only more slowly migrating bands
 .were detected with these antibodies Fig. 5B .
 .Fig. 1. Flow cytometric analysis of deferoxamine-treated cells. A Cells were harvested after 6 h of treatment. DNA histograms were
analyzed after ML-1 cells were stained with propidium iodide, as described in Section 2. The expression of p53, p21, and CDK4 was
analyzed with monoclonal antibodies against p53 and p21 and polyclonal antibody against CDK4, as described in Section 2. Blank:
 .preimmune mouse IgG for p53 and p21 detection or preimmune rabbit serum for CDK4 detection was used as the first antibody. B
DNA histogram of ML-1 cells after 48 h of treatment with 10y4 M DFO. UT: untreated, DFO: deferoxamine, Etop: etoposide. The data
are representative of three separate experiments.
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Fig. 3. Northern blot analysis. Total RNA was extracted from
ML-1 cells 3 or 6 h after the addition of 10y4 M DFO, 10y5 M
etoposide, or 10y5 M AraC. Twenty micrograms of total RNA
were electrophoresed on formaldehyde agarose gel, transferred to
Hybond Nq membrane, and hybridized with digoxigenin-labeled
 .  .  .probes. A p53, B p21, C CDK4. The level of expression was
normalized by comparison with b-actin.
To quantify the precise level of pRB and the
phosphorylation status of pRB at the serine and thre-
onine residues, we constructed an ELISA system
using chemiluminescent detection. Table 1 summa-
rizes the ELISA data obtained from four independent
experiments, each of which was performed with du-
plicate samples. The amount of pRB was calculated
from the standard assay. The amount of pRB of 9.70
ngr100 mg cell lysate of untreated cells did not
change after 6 h of treatment with DFO, 10.66 ng,
and decreased markedly after 6 h of treatment with
etoposide, 2.61 ng, or AraC, 3.32 ng.
Fig. 4. Western blot analysis of p21 protein. Cells were harvested
6 h after the addition of 10y4 M DFO, 10y5 M etoposide, or
y5  .10 M AraC and lysed with 1% NP40. A Cell lysates were
immunoprecipitated with anti-CDK4 polyclonal antibody, then
 .electrophoresed on 10% to 20% SDS-PAGE. B Cell lysates
were immunoprecipitated with anti-p21 monoclonal antibody af-
ter treatment with 0.01% SDS and 0.1% sodium deoxycolate,
then electrophoresed on 10% to 20% SDS-PAGE. The mem-
 .branes were probed with anti-p21 monoclonal antibody. C cell
 .lysate - , UT: untreated, D: deferoxamine, E: etoposide A: AraC.
The level of phosphorylation was calculated as the
 .ratio of chemiluminescence value KCOUNT ob-
tained by anti-phosphorylated serine and threonine
antibodies to the chemiluminescence value obtained
by anti-pRB antibody, which indicates the amount of
pRB. The phosphorylation level did not change after
Fig. 5. Western blot analysis of pRB. Cell lysates were prepared
6 h after the addition of 10y4 M DFO, 10y5 M etoposide, or
10y5 M AraC. Cell lysates were immunoprecipitated with anti-
pRB monoclonal antibody, and the precipitates were elec-
trophoresed with 7.5% SDS-PAGE, transferred to Hybond Nq
 .membrane, and probed with anti-pRB monoclonal antibody A
 .or anti-phosphorylated serine and threonine B . Confluent WI38
cells were used as a control for growth arrest. The data are
representative of three separate experiments. UT: untreated, DFO:
deferoxamine, Etop: etoposide.
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Table 1
ELISA data obtained from four independent experiments
Exp. 1 Exp. 2 Exp. 3 Exp. 4 Mean S.E.
( )Anti-pRB KCOUNTr20 s
UT 30.40 30.60 30.50 28.30 30.50 0.10
DFO 35.80 32.98 30.30 27.85 33.03 2.75
Etoposide 11.72 14.45 9.40 7.30 11.86 2.53
AraC 10.60 19.55 11.00 11.25 13.72 5.06
( )Anti-phosphoreserine and threonine KCOUNTr20 s
UT 5.90 5.85 5.50 6.00 5.75 0.22
DFO 7.20 5.40 4.75 5.60 5.78 1.27
Etoposide 5.20 5.70 5.75 4.80 5.55 0.30
AraC 6.10 5.25 5.50 6.60 5.62 0.44
( )pRB ngr0.1 mg cell lysate
UT 9.66 9.74 9.70 8.86 9.70 0.04
DFO 11.71 10.64 9.62 8.69 10.66 1.05
Etoposide 2.56 3.60 1.68 0.88 2.61 0.96
Arac 2.14 5.54 2.29 2.39 3.32 1.92
( ) ( )Phosphorylation le˝el: phosphoserine and threonine KCOUNT rpRB KCOUNT
UT 0.19 0.19 0.18 0.21 0.19 0.01
DFO 0.20 0.16 0.16 0.20 0.17 0.02
Etoposide 0.44 0.39 0.61 0.66 0.48 0.12
AraC 0.58 0.27 0.50 0.59 0.45 0.16
Each experiment was performed with duplicate samples.
6 h of DFO treatment, and increased somewhat after
etoposide treatment.
4. Discussion
We analyzed the cellular response to iron depriva-
tion by DFO treatment in comparison with treatment
with a DNA-damaging agent, etoposide, or an an-
timetabolite, AraC. With all three treatments, the
level of p53 mRNA did not change and p53 protein
levels increased in the G1 phase, findings that con-
w xfirm the posttranscriptional regulation of p53 10,23 .
Expression of p21 mRNA was induced by all three
treatments, suggesting that the increased p53 func-
tioned as a transcription factor. However, FACS and
Western blot analysis confirmed that p21 protein
expression increased only with etoposide, but not
with DFO or AraC treatment, suggesting that p21
gene expression may be posttranscriptionally regu-
lated. Northern blot analysis showed that treatment
with etoposide for 3 h resulted in the highest level of
p21 mRNA. For effective expression of p21 protein,
a considerable amount of p21 mRNA may be re-
quired in the early stages of the cellular response or
DNA damage may be required for translation of p21
mRNA. We conclude from these results that the G1
accumulation caused by DFO is p21-independent.
Analysis of CDK4 expression showed that al-
though mRNA levels remained constant after treat-
ment with all three agents, protein expression was
reduced by treatment with etoposide and AraC, sug-
gesting that CDK4 may have been posttranscription-
ally regulated. Ewen et al. have reported that an
increase in wild-type p53 inhibits translation of CDK4
w xmRNA 20 . In our study, p53 accumulated with all
three treatments, but CDK4 protein levels were af-
fected only by treatments with etoposide or AraC.
The elevation in p53 caused by DFO treatment was
thus ineffective in blocking CDK4 translation.
ELISA and Western blot analysis revealed that
treatment with DFO for 6 h did not affect expression
of pRB or pRB phosphorylation. After treatment with
etoposide or AraC for 6 h, expression of pRB de-
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creased and the pRB phosphorylation index in-
creased. This result may have been caused by the
failure of etoposide and AraC to arrest G1 at this
point, implying that although the cells pass through
the G1-S checkpoint, the following cell cycle did not
proceed properly, and, therefore, pRB was not de-
phosphorylated. Since we assayed the native form of
pRB with ELISA, the bead-coated anti-pRB mono-
clonal antibody or the anti-pRB polyclonal antibody
might not have detected pRB in the complex. In this
assay, both antibodies recognize regions outside the
w xpocket domain or phosphorylation region 22 and the
results of ELISA paralleled those of Western blot
analysis. Thus, results with the present ELISA system
were considered reliable.
In this study, we found that although p53 accumu-
lation occurred with all three treatments, the down-
stream cellular response was variable. Treatment with
DFO clearly caused G1 accumulation; accordingly, a
growth inhibition mechanism may exist indepen-
dently from the cascade by which p53 induces p21,
which inhibits CDK4 activity, and results in pRB
phosphorylation. Recent studies have revealed that
p21-deficient mouse embryo fibroblasts undergo G1
w xarrest after DNA damage 23,24 . Growth inhibition
by iron deprivation would thus offer a model system
to analyze the regulation of cell growth by mecha-
nisms other than p53-inhibition of pRB phosphoryla-
tion.
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